Goldman Sachs
BIVV

Goldman Sachs’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Goldman Sachs’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,143,890
Closed -$61.7M – 6656
2017
Q4 		$61.7M Sell
1,143,890
-1,156,539
-50% -$63.3M 0.01% 1131
2017
Q3 		$131M Buy
2,300,429
+716,021
+45% +$41.9M 0.03% 654
2017
Q2 		$95.3M Buy
1,584,408
+1,173,601
+286% +$66.8M 0.02% 800
2017
Q1 		$22.4M Buy
+410,807
New +$20.2M 0.01% 1806

Other funds holding BIVV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
ACS
Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Goldman Sachs's BIVV Position: Q1 2018 in Review

Goldman Sachs sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 1,143,890 shares — an estimated $61.7M sold.

Goldman Sachs first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $131M in Q3 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

  • Goldman Sachs reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Goldman Sachs sold 1,143,890 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $61.7M.
  • Goldman Sachs first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
  • Goldman Sachs's Bioverativ Inc. Common Stock position peaked at $131M in Q3 2017.
  • 2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Goldman Sachs's 13F filing for Q1 2018, filed 15 May 2018.